Yago Garitaonaindía · @YGaritaonaindia“☢️ KEYNOTE-867 in @JCO_ASCO: SBRT ± pembrolizumab in unresected stage I-II #NSCLC (phase 3, n=448) 🪶Prof. Pircher ➡️ mEFS 31.2 vs 28.3 months | HR 0.92 (0.69-1.24) ➡️ OS HR 1.33 (0.93-1.90), numerically worse in the IO arm ➡️ G3-5 TRAEs 20.4% vs 3.7% ➡️ 5 treatment-related deaths, all with pembro Stopped early at the first interim analysis (median follow-up 20.6 months). 🔍 The <65y signal (EFS HR 0.48) rests on 66 patients and 20 events. Concurrent IO + RT is not a good strategy in early-stage NSCLC. @_SEOM @oncodaily @OncodailyLung @OncoReporte #LCSM”
View post ↗Full Lung Cancer coverage in today's digest →A non-randomized phase II study of neoadjuvant ivonescimab in resectable NSCLC (Nature Medicine) showed MPR 60% and pCR 30% with ivonescimab alone (n=10), and MPR 70% and pCR 51% with ivonescimab plus chemotherapy (n=67; pCR 61% in squamous), with 1 treatment-related surgery delay. Ivonescimab is investigational. The KEYNOTE-867 publication in JCO added an OS HR of 1.33 (0.93–1.90), numerically worse with pembrolizumab added to SBRT in stage I–II NSCLC, with 5 treatment-related deaths, all in the pembrolizumab arm.
“Wow! If such high pCR rates are replicated in larger trials, we next need to identify reliable algorithms to predict pCR and determine whether there are patients in whom we can omit surgery.”
— @BrendonStilesMD · Neoadjuvant ivonescimab · View post ↗
“Poor partner, wrong setting, or both?”
— @StephenVLiu · KEYNOTE-867 · View post ↗“Concurrent IO + RT is not a good strategy in early-stage NSCLC.”
— @YGaritaonaindia · KEYNOTE-867 · View post ↗📌 Amplified by @KolPulseAI
In an abstract to be presented at SABCS 2026, the HER2 ADC IKS014 (caxmotabart entudotin) showed an ORR of 50% (5/10) in HER2-positive metastatic breast cancer previously treated with T-DXd. IKS014 is investigational. Dr. Paolo Tarantino placed the result alongside earlier payload-switch data from DB02 and TULIP.
“Switching ADC payload works.”
— @PTarantinoMD · ADC sequencing · View post ↗The phase 2 UNICORN trial (Nature Medicine) gave short-course neoadjuvant botensilimab, an Fc-enhanced anti-CTLA-4, with or without the anti-PD-1 balstilimab, to patients with resectable T3–4 colon cancer in four cohorts of 14 (N=56). In pMMR disease, major pathological response was 0% with botensilimab alone and 36% with the combination (pCR 29%); in dMMR disease, the combination gave MPR 100% and pCR 93%. Both drugs are investigational, the cohorts are small and non-randomized, and survival follow-up is immature.
“Every MSS responder cleared ctDNA before surgery, that’s a helpful tool for predicting response in a disease that may fibrose and stay visible on imaging.”
— @GIMedOnc · ctDNA and response · View post ↗
“The results in pMMR were particularly surprising and far exceeded my expectations.”
— @dr_yakupergun · pMMR response · View post ↗
“The 93% pCR in dMMR is remarkable, but the 36% major pathological response in pMMR may be the more biologically provocative signal.”
— @DrRishabhOnco · pMMR vs dMMR · View post ↗
“Small sequential cohorts and no survival data yet”
— @DrAllanPereira · Limitations · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
The phase 3 ENERGIZE trial (CA017-078, n=653) of neoadjuvant nivolumab plus gemcitabine-cisplatin followed by adjuvant nivolumab in cisplatin-eligible MIBC met neither co-primary endpoint: EFS HR 0.94 and pCR 39.1% vs 29.6%, not statistically significant (Annals of Oncology). Mature THOR data for erdafitinib vs chemotherapy in metastatic urothelial cancer showed OS 12.1 vs 8.7 months (HR 0.65) and ORR 46.9% vs 12.6%. The investigational ENPP3×CD3 T-cell engager XmAb819 showed a confirmed ORR of 45.5% (5/11) at 400 µg/kg in heavily pretreated ccRCC.
“Neither co-primary endpoint was met: EFS HR 0.94; pCR 39.1% vs 29.6% (not statistically significant).”
— @drenriquegrande · ENERGIZE · View post ↗
“Precision targeting works. Now we need to make responses last.”
— @niklas_kluemper · THOR · View post ↗Dr. Aaron Goodman wrote that the guidelines' preferred options for relapsed myeloma are bispecific T-cell engagers or CAR-T, and called for an end to NCI trials randomizing patients to what he described as substandard therapy. Dr. Breno Moreno de Gusmão proposed a four-state framework for joint MRD and PET reporting. Dr. Robert Orlowski highlighted a UK NHS real-world study in which NGS re-classified 2% of newly diagnosed patients as high-risk.
“Time to stop the NCI trials randomizing patients to substandard therapy.”
— @Papa_Heme · Relapsed myeloma guidelines · View post ↗📌 Amplified by @KolPulseAI
“MRD-neg/PET-pos and MRD-pos/PET-neg are not just assay disagreement.”
— @morenodegusmao · MRD + PET · View post ↗Dr. Jose Sandoval described a persistent signal of effectiveness for bispecific antibodies in CNS lymphomas, with prospective trials still pending. A meta-analysis examined survival by phased-variant ctDNA and PET response in large B-cell lymphoma. Dr. Aaron Goodman wrote that it is increasingly difficult in oncology to determine whether a cancer therapy is futile.
“This is a persistent signal of effectiveness for BsAbs in CNS lymphomas!”
— @HemSandoval · CNS lymphoma · View post ↗“It is getting increasingly difficult in oncology to determine whether offering a cancer therapy is truly futile or not.”
— @Papa_Heme · Futility · View post ↗